Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height - Fig 1

<p>A: Change in height-SDS for an unselected group of patients receiving rhGH after one year of treatment against BMI-SDS at initiation of prescription. Change in growth p = 0.041 (ANOVA) B: Change in height-SDS for patients with growth hormone deficiency and receiving rhGH after one year of treatment against BMI-SDS at initiation of prescription. Change in growth p = 0.005 (ANOVA) C: Change in IGF-1-SDS after one year of treatment against BMI-SDS at initial rhGH prescription for an unselected group of patients. Change in IGF-1 p<0.0001 (ANOVA) D: Change in IGF-1-SDS after one year of treatment against BMI-SDS at initial rhGH prescription for patients with growth hormone deficiency. Change in IGF-1 p<0.0001 (ANOVA).